Printable version: 
Fact sheet as of April 20, 2023
SEB Medical Fund
The fund invests in equities and equity-related securities in the healthcare sector across the world.
Fund manager:  Angelica Fatouros
Investment Philosophy

Generally accepted financial theory claims the investor is rational, the market is efficient and the only way to generate excess return is to assume higher market risk (beta). The investment team believes that higher market risk does not always result in a proportionally higher return, thus investors are not always fully compensated for assuming greater risk. This is substantiated by recent research. The investment team is also of the opinion that market information is generally not interpreted consistently by market actors. A structured, rule-based investment process is objective in evaluating market risk and market information. Accordingly, we believe this type of investment process provides the best chance of utilising these two anomalies in order to generate better-than-market returns.

Key Facts
Base CurrencyUSD
Share ClassD (USD)
BenchmarkMSCI World Heal...
Year of launch1993
Value at launch (USD)1.00
Legal StructureUCITS
Fund Management CompanySEB Investment Management AB
Turnover Ratio*0.43
* 12 months rolling, last updated 31 Mar 2023
When applicable, dividends are paid in cash the subsequent fiscal year.
Management Fee1.50
Ongoing Charges*1.55
Entry FeeMax 5%
* The ongoing charges includes the management fee and constitutes payment for fund management, including marketing and distribution. The ongoing charges does not include transaction costs such as brokerage commissions on securities transactions.
Risk Measures (USD)*
Standard Deviation (Fund)15.6
Standard Deviation (Index)14.6
Tracking Error2.5
Active share **55.9
Sharpe Ratio0.4
Information Ratio-1.7
* 36 months rolling, last updated 30 Apr 2023
** Active share measures the difference between the fund’s and the benchmark’s holdings. From 31 Mar 2023
Investment Process

Investment universe

The fund invests globally in equities and equity-related securities in healthcare and biotechnical companies, medical service or technological companies, as well as the health and medical care segment. The healthcare sector is regarded as less sensitive to economic fluctuations than many other sectors, and the yield is dependent to a great deal on medical progress and scientific advances. In view of that the fund invests outside Sweden, the fund's asset value is affected by movements of the Swedish krona in relation to other currencies. The fund has the possibility to use derivative instruments.

Investment team

The fund is managed by the Global Equities team (QPM) within SEB Investment Management AB. The team, based in Stockholm, employs a rule-based systematic and disciplined investment process.


The team uses a rule-based investment process based on evaluating the quality, profitability, valuation, sentiment, and risk profiles of individual companies which are potential investment objects. These factors form the basis for an objective ranking that identifies attractive companies. The team’s rule-based approach makes it possible to include all the companies in the investment universe in the evaluation process.

Portfolio construction

The portfolio is built from a bottom-up perspective. In constructing the portfolio, the team focuses on selecting the holdings that will result in the intended active exposure and risk profile for the portfolio. The investment team also aims to maintain diversification, efficient execution and cost-effective implementation.

Performance (USD)
Currency: USD        |        NAV: 9.13 (4/20/2023)        |        AuM (M USD) : 45.67 (3/31/2023)
SEB Medical Fund (FundUSD)MSCI World Health Care Net Return Index (Benchmark, )
 Fund USDBenchmark
Return % USDFundBenchmark
Accumulated since  
1 day0.0-0.3
1 month6.36.6
3 months0.81.6
6 months10.613.1
1 year-5.1-2.2
3 years17.432.6
5 years36.965.7
Year to date--
Average annual growth  
3 years5.59.9
5 years6.510.6
CurrencyAdd benchmark
Open the calendar popup.
Open the calendar popup.
Largest Positions*
% of Total  
 % of Total
Novo Nordisk6.2
Eli Lilly5.4
UnitedHealth Group4.8
Johnson & Johnson3.8
Boston Scientific Corp3.0
Daiichi Sankyo Co Ltd2.7
Vertex Pharmaceuticals Inc2.6
Thermo Fisher Scientific Inc2.5
* Last updated 31 Mar 2023. Source: SEB
* Numbers are absolute, not relative
Other Information

As of 1 February 2021 the funds has a new fund manager. As of 2 November 2016, the fund´s Management company is SEB Investment Management AB.

This material is prepared by SEB and contains general information regarding financial instruments marketed, sold or solicited by SEB. SEB is the global brand name for Skandinaviska Enskilda Banken AB (publ), its subsidiaries and affiliated companies. Neither this material nor the products described in it are intended for distribution or sale in the United States or to US persons, and any such distribution is not allowed. The offering of shares or units in the funds may also be restricted in other jurisdictions. This document may not be used to make an offer or solicitation with respect to the sale of shares or units where such an offer or solicitation is unlawful. Although the information in this material is based on sources deemed by SEB to be reliable, SEB assumes no liability whatsoever for incorrect or missing information or for any loss, damage or claim arising from the use of this material. Past performance does not guarantee future performance. The value of investment funds and other financial instruments may rise as well as fall and there is no guarantee you will recover your original investment. If you or a fund invests in financial instruments denominated in a foreign currency, changes in currency exchange rates can affect the return on the investment. SEB makes no representation that funds whose share or unit classes aim at hedging the fund’s return from changes in currency exchange rates will succeed in achieving this. Any tax information in this material is based on regulations valid as per the date of this presentation and may be subject to change. Note that any tax information in this material is general. Kindly contact your SEB investment advisor for tax and investment advice appropriate for your situation. You are fully and solely responsible for your investment decision. This material is not intended for or suitable as the sole basis for investment decisions. Instead, you should base your decision on the information in the fund’s product documentation, including its fact sheet, Key Information Document, fund regulations and prospectus. These are available on
Tuesday, December 5, 2023 6:31:28 PM